There is a newly created Tasigna multi-district litigation (MDL) for those Tasigna drug injury lawsuits filed in the federal court system. We get some of the reasoning for this consolidation of Tasigna side effects cases from the August 10, 2021, JPML Transfer Order issued for IN RE: TASIGNA (NILOTINIB) PRODUCTS LIABILITY LITIGATION, MDL No. 3006:
All actions can be expected to share factual questions arising from allegations that Novartis failed to appropriately warn of the risks that use of Tasigna may cause severe atherosclerotic injuries. Despite warning doctors and patients in Canada of the heightened risks of atherosclerotic-related conditions, plaintiffs contend that Novartis concealed its knowledge of Tasigna’s unreasonably dangerous risks from plaintiffs, other consumers, and the medical community in the U.S. All plaintiffs bring claims for strict products liability – failure to warn and negligence. Issues of general causation and Tasigna’s labeling and regulatory history appear common to all actions….
Novartis opposes centralization, arguing that there are too few actions to justify centralization and that informal cooperation is feasible. We are not persuaded by these arguments…. [Footnotes omitted.]
As we previously, in early June 2021, the New Jersey Supreme Court consolidated some other Tasigna drug injury lawsuits filed against Novartis for pretrial proceedings as part of a New Jersey state court multi-county litigation (MCL).
Here is what one needs to know about these Tasigna drug injury cases. Since at least 2013 Tasigna has been linked to atherosclerosis, which is a disease that results in thickening, hardening, and blocking of the arteries due to the buildup of plaque. The following medical conditions are considered to be atherosclerosis-related diseases:
Peripheral Arterial Disease (PAD) involving lower limbs;
Peripheral Arterial Occlusive Disease (PAOD);
Ischemic Heart Disease; and,
Ischemic Cerebrovascular Disease.
In turn, these serious medical conditions can result from, or are secondary to, atherosclerosis-related diseases:
Strokes / Cerebrovascular Accidents (CVA)
Heart Attacks / Myocardial Infarctions (MI)
Lower Limbs Amputations
Aneurysms, e.g., Brain Aneurysm
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Chronic Kidney Disease
Kidney / Renal Failure
As such, these various medical conditions are considered to be Tasigna side effects.
For the past few years, well before these recent Tasigna MDL and Tasigna MCL orders, we have been investigating Tasigna drug injury lawsuits against Novartis for patients who were diagnosed with an atherosclerosis-related disease and thereafter suffered subsequent Tasigna side effects, such as an amputation, aneurysm, stroke, or heart attack.
[View article in full at original source]